⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26023698 | 0.87 | AR (0.34) | — | |
| SCHEMBL25315851 | 0.87 | AR (0.34) | — | |
| SCHEMBL31436512 | 0.74 | ESR2 (0.30) | — | |
| SCHEMBL31349425 | 0.74 | HCAR1 (0.33) | — | |
| SCHEMBL25319216 | 0.72 | CYP2C9 (0.32) | — | |
| SCHEMBL25924914 | 0.72 | CYP2C9 (0.32) | — | |
| SCHEMBL31436508 | 0.72 | AR (0.34) | — | |
| SCHEMBL25315199 | 0.71 | AR (0.32) | — | |
| SCHEMBL25924390 | 0.71 | AR (0.32) | — | |
| SCHEMBL25924609 | 0.71 | IDH1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025015106-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |